Regulatory Milestones

Alimera Sciences Inc. (NASDAQ:ALIM) lost $0.10 to $7.06 last week after submitting an MAA for Iluvien to treat diabetic macular edema (DME). Alimera, which has rights from pSivida Corp. (NASDAQ:PSDV; ASX:PVA), submitted an NDA to FDA for the injectable insert delivering fluocinolone acetonide (FA) to the retina earlier this month. pSivida gained $0.23 to $3.50 last week.

Dyax Corp. (NASDAQ:DYAX) lost $0.02 to $2.25 last week after EMA accepted for filing an MAA for ecallantide to treat acute attacks of hereditary angioedema (HAE). Dyax markets the subcutaneously delivered yeast-derived recombinant plasma kallikrein inhibitor as Kalbitor in the U.S...